Targeted therapeutic agents have demonstrated clinical efficacy in treating NSCLC patients with EML4-ALK gene fusion, but also in treating tumors with ALK fused with other partner genes, including NPM1 and BCL11A [22]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.